TL;DR
This paper demonstrates the successful development and preclinical evaluation of 64Cu-PSMA-617, a novel radiotracer for PET imaging. The study shows that this tracer can effectively visualize gastric adenocarcinoma xenografts in mice, highlighting its potential as a diagnostic tool for this challenging cancer.
What Problem Does This Paper Address?
Gastric cancer is a significant global health concern, particularly in Asia, and is often diagnosed at advanced stages, leading to poor prognoses. Current imaging methods like CT and MRI have limitations in accurately staging the disease and detecting metastatic lesions. While 18F-FDG PET is widely used, it suffers from limited sensitivity and specificity for gastric cancer. The researchers aimed to address this by exploring the potential of targeting Prostate-Specific Membrane Antigen (PSMA), which has been found to be overexpressed in the neo-vasculature of various solid tumors, including gastric carcinomas, offering a new avenue for molecular imaging.
Methods
The core of this study involved:
- Radiosynthesis: Synthesizing the 64Cu-labeled PSMA-617 radiotracer. This involved radio-labeling the DKFZ-PSMA-617 ligand with the radionuclide 64Cu.
- In Vitro Characterization:
- Stability Testing: Assessing the stability of 64Cu-PSMA-617 in human serum albumin (HSA) and saline at 37°C to ensure it remains intact for imaging.
- Cell Uptake Assays: Evaluating the specificity of the radiotracer by testing its uptake in PSMA-positive (LNCaP) and PSMA-negative (PC-3, BGC-823) cancer cell lines. Blocking studies with a known PSMA inhibitor (ZJ-43) were performed to confirm specific binding.
- In Vivo Evaluation:
- Micro-PET Imaging: Performing positron emission tomography (PET) imaging in nude mice bearing BGC-823 (gastric adenocarcinoma) and PC-3 (prostate cancer) xenografts to visualize tumor uptake. Blocking studies with ZJ-43 were also conducted in vivo.
- Biodistribution Studies: Administering the radiotracer to normal mice and tumor-bearing mice to determine its distribution in various organs over time.
- Auto-radiography and Immunohistochemistry: Analyzing dissected tumor tissues to confirm PSMA expression in the tumor-associated neo-vasculature and correlate it with tracer uptake.
Datasets
The study utilized established cancer cell lines:
- LNCaP: A PSMA-positive human prostate cancer cell line.
- PC-3: A PSMA-negative human prostate cancer cell line.
- BGC-823: A human gastric adenocarcinoma cell line.
Animal models were created using these cell lines in nude mice. No new datasets were introduced; the focus was on evaluating the performance of the radiotracer in established preclinical models.
Key Insights and Ideas
- PSMA as a Target for Gastric Cancer: The study strongly supports the idea that PSMA, traditionally a target for prostate cancer, is also a viable target for imaging gastric adenocarcinoma, specifically by targeting its neo-vasculature.
- 64Cu-PSMA-617 Shows Promising Specificity: The in vitro cell uptake data clearly demonstrated that 64Cu-PSMA-617 binds specifically to PSMA-expressing cells and that this binding can be effectively blocked by a PSMA inhibitor.
- In Vivo Tumor Visualization: Micro-PET imaging successfully visualized gastric adenocarcinoma xenografts in mice, with good tumor-to-background ratios achieved up to 24 hours post-injection.
- Blocking Confirms Specificity: The in vivo blocking studies with ZJ-43 significantly reduced tumor uptake, further confirming the PSMA-specific targeting of the radiotracer in the tumor microenvironment.
- Neo-vasculature as the Key Target: Auto-radiography and immunohistochemistry provided crucial evidence that PSMA expression in the neo-vasculature of the tumor periphery is responsible for the observed tracer uptake, explaining its utility beyond just tumor cells.
Key Results
- Radiosynthesis: 64Cu-PSMA-617 was synthesized with high radio-chemical yield and specific activity (up to 19.3 GBq/µmol).
- In Vitro Stability: The radiotracer showed good stability in saline (94% intact after 24h) and reasonable stability in 5% HSA.
- Cell Uptake: Significant uptake was observed in LNCaP cells, while uptake in PC-3 and BGC-823 cells was significantly lower and could not be effectively blocked, confirming low PSMA expression in these cell lines.
- Micro-PET Imaging: Tumors were clearly visualized in BGC-823 xenografts as early as 0.5 hours post-injection, with good contrast maintained up to 24 hours. Similar results were observed in PC-3 xenografts.
- Biodistribution: High uptake was observed in the liver and kidney, with moderate uptake in tumors. Salivary glands also showed uptake, which was blocked by ZJ-43.
- Blocking Efficacy: Co-administration of ZJ-43 substantially blocked tumor uptake in vivo, indicating specific targeting.
Limitations and Future Work
- Salivary Gland Uptake: The study noted uptake in salivary glands, which is a known non-specific uptake site for PSMA-targeted agents. While this was observed, the tumor-to-salivary gland ratio improved over time.
- DOTA Chelator: The authors suggest that while DOTA is a suitable chelator, it might not be the "perfect selection" for 64Cu chelation, implying potential for further optimization of the chelator for improved performance.
- Further Improvements Needed: The paper concludes by stating that further improvements of 64Cu-PSMA-617 are needed, particularly in terms of its selection as a chelator.
- Clinical Translation: While the preclinical results are promising, further clinical studies are necessary to validate its efficacy and safety in human patients with gastric cancer. The authors suggest that the similarity to other PSMA-based tracers could facilitate its translation.
Summary updated